

*Corporate Presentation of*

# nDatalyze Corp. / EpitomePD

CSE: NDAT | OTC: NDATF

December 2026

IMPORTANT NOTICE

# Forward Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

## The Question

Why is it that most people exhibiting high-performance potential at younger ages, regardless of the profession, don't convert that potential to sustained high performance as they age?

## The Answer

**Because they didn't maximize their natural predispositions.**

While all people share most human genetics, there are numerous small differences that affect each person's predispositions to both mental and physical high performance. There are also differences in what each person experiences during his/her formative years.

Genetic foundation and environmental experiences combine to create a unique "build" for each person. Certain builds are predisposed to sustained high performance, regardless of profession. EpitomePD is designed to identify predispositions based on scientifically-studied objective data.

While predispositions are not guarantees, knowing them provides a superior foundation for highly-personalized training routines that can optimize natural abilities, thereby contributing to long term high performance.



## Meet EpitomePD, by nDatalyze Corp.

“The hockey player *decoded*.”

EpitomePD turns genetic and mindset data into a measurable development plan for every hockey player.

### Two products, one dossier

A 90-item mindset assessment and a 22-marker genetic test kit

### Built on reference data

Scores are set against a baseline of >1,000 reference participants

### Personalized to the player

Personalized PDF report, profile archetype and monthly actions

THE FIRST COMMERCIAL PRODUCT OF NDATALYZE CORP.

CSE: NDAT | OTC: NDATF

# A clinically studied foundation

EpitomePD is the hockey-focused extension of a multi-year, multi-million-dollar clinical psychological assessment project, hardened with mental and physical performance predispositions in hockey. Senior personnel from junior hockey teams, prestige hockey academies and psychoanalysts steered the scoring algorithms.

**>1,000**
Reference participants

**250**
Calibration items

**EEG**
Biometric validation

**90%+**
Clinical-study accuracy

### 01 Discovery

**An accredited research facility gathers objective biometric data, including EEG, from 1,200+ people.**

### 02 Validation

**A clinical study with York University correlated genetic and environmental data to predict depression with greater than 90% accuracy.**

### 03 Calibration

**250 calibration items were tuned into a 90-item hockey-calibrated mental assessment. Together with a cheek-swab genetic kit, they produce two personalized reports – one of mind, one of genome – covering 22 hockey-relevant genetic markers and 90 psyche prompts included in the personal archetype monthly action player dossier.**

# What the Hockey Experts Who Helped Develop EpitomePD Say About the Assessment Reports

## Willie Desjardins

**Medicine Hat Tigers**

Head Coach & General Manager

2025

*"By combining a player's development data and genetic data, the predisposition report significantly enhances talent assessment and provides unique insights supporting personalized skill development. There is lots of value here."*

## Mike Johnston

**Portland Winterhawks**

President & General Manager

2025

*"The report's genetic data offered new insights into player potential and limitations, allowing for the creation of individualized training plans. By evaluating mindset scores, the team identified the need to develop mental skills in certain players to improve their long-term performance. The hockey attitude score was crucial for understanding how young athletes manage adversity both on and off the ice. Overall, the analysis serves as a comprehensive tool for player development across different competitive levels. This unique report provides valuable feedback for coaches, management, and players alike."*

## TJ Manastersky

**Brock University Badgers**

Head Coach

2025

*"Epitome provides objective, data-driven insights that empower players to own their growth while positioning coaches as supportive partners in tailored development planning. By highlighting specific mental and physical needs, it serves as a high-value tool for optimizing team performance and informing strategic scouting decisions."*

# Nobody measures the mind or the genome

Long-term elite performance is primarily a function of mental state. Physicality may get a player to the majors; barring injury, it is the mind that keeps them there.

### Coached every day

Skating · shooting · strength · systems · video

### Measured by no one

Composure under pressure · recovery after mistakes · resilience · genetic predisposition

### Stop guessing

The rest of the league is still training on intuition. The next era of hockey belongs to the precisely informed.



THE INVISIBLE HALF

## 1 of 1

Every player's mindset and genome are unique. EpitomePD makes that half of the game visible, scored, and trainable.

# Predisposition, turned into a plan

Two objective inputs — a 90-item hockey-calibrated mindset assessment and a 22-marker genetic kit — produce one personalized, human-reviewed player dossier.

**01**

### Know your mental edge

Quantify composure, focus, resilience and decision-making under pressure.

**02**

### Find what holds you back

Pinpoint the mental and genetic factors limiting the game, each with a next step.

**03**

### Get a plan, not a score

A profile archetype plus three tailored actions to work on this month.

**04**

### Engineer the next level

Train the invisible half of the game against a measurable blueprint.

*Reports are owned by the player and their family — players and families can choose to share their own report with a coach or team therapist.*

# Inside the assessment

## HOW IT RUNS

**01 Complete the assessment**

90 hockey-calibrated prompts, 30 of them hockey-specific, in about 35 minutes.

**02 Scoring against the baseline**

Responses are scored against a >1,000 person clinical reference database.

**03 Human review**

A credentialed reviewer checks the profile before the dossier is released.

**04 Report in the dashboard**

An instant personalized PDF plus the dashboard profile, owned by the family.

## WHAT IT SCORES

**Hockey Attitude**

Coachability, team-first habits, consistency

**Psychological Performance**

Resilience and recovery after mistakes

**Anxiety**

Calibrated to a high-performance window, not minimized

**Depression**

Mood baseline and downside risk

**Overall Mindset**

The composite score and profile archetype

# Sample report: scores against the baseline

**Illustrative sample data from the published example report — a real dossier is generated from the player's own responses and genetic results.**




OVERALL MINDSET

**7.4**

out of 10 · Strong

| | |
|---|---|
| Hockey Attitude | **7.8 · Strong** |
| Psych Performance | **7.0 · Solid** |
| Anxiety | **3.4 · Optimal** |
| Depression | **2.1 · Healthy** |

SAMPLE ARCHETYPE **The Composed Competitor** — steady under pressure, sharper when it matters. Anxiety between 2 and 4.5 (and above Depression) is the target window.

# From score to archetype to homework

YOUR ARCHETYPE

## The Composed Competitor

Steady under pressure, sharper when it matters. Reads pressure as a signal to focus rather than a threat — a trait pro environments prize.

STRENGTHS AND WATCH-OUTS

**Hockey Attitude**
Strong — coachable, team-first, consistent habits

**Anxiety**
Optimal — enough edge to stay engaged

**Psych Performance**
Solid — recovery after errors is the lever to lift output

THREE THINGS TO TRY THIS MONTH

**01** Run a 90-second pre-game breathing and visualization routine before every warm-up.

**02** Mentor one teammate per week on a small detail — it reinforces accountability.

**03** Log a two-line reflection after each game: one thing that worked, one to adjust.

*Reports are human-reviewed, and every profile ships with actions a player can start.*

# The scale: one assessment, many markets

## SPORTS









EpitomePD, Hockey

## C-SUITE



## HEALTH SERVICES



# nDatalyze Corp. (NDAT | NDATF)

**SHARE CAPITAL**

## 41,327,425

shares issued & outstanding (CSE)

Public float ~30M shares

Fiscal year-end February 28

Management ownership ~22%

**MARKET VALUE**

## ≈ $2.9M

CAD market cap, Nov 18, 2026

CSE last C$0.07; 52-wk range C$0.01 – C$0.20

Nov 18 volume: 241,920 shares

OTC (NDATF): US$0.08; 52-wk US$0.011 – US$0.08

nDatalyze Corp. (CSE: NDAT | OTC: NDATF, Calgary) owns 100% of the EpitomePD technology.

Sources: CSE, Quotestream, StockAnalysis, Yahoo Finance, as of Nov 18–19, 2026. Delayed data; not investment advice.

# Upside / Blue Sky

**01**

Multiple market opportunities

**02**

Significant development “moat” due to proprietary databases

**03**

Low market cap

**04**

Beginning of revenue cycle

# Corporate Management

| | |
|---|---|
| **D'Arcy Funfer**<br>President & CEO | D'Arcy brings more than 40 years of investment industry experience, specializing in capital markets, financing, trading, and market liquidity programs. He has held senior leadership roles supporting public companies, investors, and financial institutions, aligning capital markets strategies with corporate growth and shareholder value. |
| **James Durward**<br>Founder, Chairman & CTO | Jim is a data scientist with over a decade of experience in image analysis, pattern recognition, and database development. He is a patented, published inventor with extensive public company experience. |
| **Dusan Kuzma**<br>MBA, MSc, Director | Experienced in product development and commercialization, Dusan has served on the advisory board for advanced manufacturing technologies in Canada at the Information and Communications Technology Council. |
| **Dwayne Vinck**<br>CA, CFO | As a qualified auditor, Dwayne brings financial reporting, directorships, executive leadership, change management, and project leadership. He also has experience in mergers and acquisitions and public company experience. |
| **Steve Price**<br>P.Eng, Director | With over 35 years of experience in engineering and management, including corporate operations, evaluations, and facilities design and operation, Steve brings valuable expertise. He also has public company experience. |

# Contact

For any questions about nDatalyze Corp. / EpitomePD please contact


## D’Arcy Funfer

President & CEO

Corporate and Investor Inquiries

403.828.2200 | dsfunfer@gmail.com

## James Durward

Founder, Chairman & CTO

Technical Inquiries

403.689.3901 | jimdurward72@gmail.com